Laboratory Co. of America Holdings (NYSE:LH) Director Kerrii B. Anderson Sells 500 Shares

Laboratory Co. of America Holdings (NYSE:LH - Get Free Report) Director Kerrii B. Anderson sold 500 shares of the stock in a transaction that occurred on Wednesday, June 11th. The shares were sold at an average price of $260.00, for a total value of $130,000.00. Following the completion of the sale, the director now directly owns 12,666 shares of the company's stock, valued at $3,293,160. The trade was a 3.80% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

Laboratory Co. of America Stock Performance

Shares of Laboratory Co. of America stock traded up $0.20 during trading on Friday, hitting $261.85. 36,370 shares of the stock were exchanged, compared to its average volume of 635,372. The company has a debt-to-equity ratio of 0.67, a quick ratio of 1.30 and a current ratio of 1.44. Laboratory Co. of America Holdings has a 12 month low of $192.38 and a 12 month high of $262.13. The stock's fifty day moving average is $239.71 and its 200 day moving average is $239.34. The stock has a market cap of $21.92 billion, a PE ratio of 29.69, a P/E/G ratio of 1.71 and a beta of 0.81.

Laboratory Co. of America (NYSE:LH - Get Free Report) last posted its earnings results on Tuesday, April 29th. The medical research company reported $3.84 EPS for the quarter, topping the consensus estimate of $3.73 by $0.11. The firm had revenue of $3.35 billion during the quarter, compared to analysts' expectations of $3.41 billion. Laboratory Co. of America had a net margin of 5.73% and a return on equity of 15.29%. Laboratory Co. of America's quarterly revenue was up 5.3% on a year-over-year basis. During the same quarter in the prior year, the firm earned $3.68 EPS. As a group, sell-side analysts anticipate that Laboratory Co. of America Holdings will post 16.01 EPS for the current year.

Laboratory Co. of America Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, June 11th. Stockholders of record on Thursday, May 29th were issued a $0.72 dividend. This represents a $2.88 annualized dividend and a dividend yield of 1.10%. Laboratory Co. of America's dividend payout ratio (DPR) is presently 33.29%.

Wall Street Analyst Weigh In

LH has been the topic of a number of recent research reports. Piper Sandler restated a "neutral" rating and issued a $280.00 target price (up from $260.00) on shares of Laboratory Co. of America in a report on Tuesday, May 6th. Truist Financial raised their price target on shares of Laboratory Co. of America from $274.00 to $290.00 and gave the company a "buy" rating in a report on Monday, May 12th. Barclays boosted their price objective on Laboratory Co. of America from $240.00 to $250.00 and gave the stock an "equal weight" rating in a research note on Wednesday, April 30th. Wall Street Zen downgraded shares of Laboratory Co. of America from a "buy" rating to a "hold" rating in a research note on Friday, April 18th. Finally, Morgan Stanley raised their price objective on Laboratory Co. of America from $270.00 to $283.00 and gave the company an "overweight" rating in a research note on Wednesday. Four investment analysts have rated the stock with a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $274.00.

Institutional Investors Weigh In On Laboratory Co. of America

Several hedge funds and other institutional investors have recently added to or reduced their stakes in LH. Graney & King LLC bought a new stake in shares of Laboratory Co. of America in the 4th quarter worth $26,000. Golden State Wealth Management LLC grew its holdings in Laboratory Co. of America by 88.1% during the first quarter. Golden State Wealth Management LLC now owns 111 shares of the medical research company's stock worth $26,000 after acquiring an additional 52 shares during the period. North Capital Inc. bought a new stake in Laboratory Co. of America in the first quarter worth about $27,000. TruNorth Capital Management LLC acquired a new stake in Laboratory Co. of America in the 1st quarter valued at about $28,000. Finally, Larson Financial Group LLC boosted its position in shares of Laboratory Co. of America by 140.4% during the 1st quarter. Larson Financial Group LLC now owns 125 shares of the medical research company's stock valued at $29,000 after purchasing an additional 73 shares in the last quarter. Institutional investors own 95.94% of the company's stock.

About Laboratory Co. of America

Labcorp Holdings, Inc engages in providing medical testing services. The company was founded on April 16, 2024 and is headquartered in Burlington, NC.